Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) has awarded $4.5m, 16-month grant to Derma Sciences to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure.
Subscribe to our email newsletter
DSC127 is a novel angiotensin analog, which has been shown to improve epithelialisation, granulation, vascularisation, and accelerate wound healing in a variety of normal and diabetic animal models.
The contract is a part of the HHS radiological and nuclear threats preparedness strategy, and could be extended for a total of five years and up to a total of $14m.
Derma Sciences had recently reported positive results from Phase II study evaluating DSC127 in diabetic foot ulcer healing.
The results showed that 54% of wounds healed completely in 12 weeks, compared to only 33% of wounds in patients receiving placebo and best standard of care in the intent to treat populations.